Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06532656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06532656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 20, 2024
Completion date
December 31, 2030
Enrollment
75 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection